Orano Med (a subsidiary of the Orano Group), a strongly engaged in the development of targeted alpha therapies for oncology, recently laid the foundation stone for its ATLab (Alpha Therapy Laboratory) in Onnaing (France, 59). This will be Europe's first industrial-scale pharmaceutical facility dedicated to the production of lead-212 based radioligand therapies.
ATLab Valenciennes, with over 3,000 m² of floor space, will represent an investment of €29 million and will create 25 direct jobs. It will focus on the production of lead-212 therapies developed by Orano Med and their distribution in Europe. Orano Med is due to inaugurate a similar facility this year in Indianapolis to serve the US market.
This combined capacity will enable Orano Med to manufacture 10,000 doses a year as of 2025, with the aim of producing ten times that number by the end of the decade. Given the short half-life of lead-212 (10.6 hours), the drugs need to be produced close to hospitals. The construction of further ATLabs is therefore envisaged to meet patients' needs worldwide.
To read more please visit:
Source: Orano